Article Focuses on how Main Physicians are Incorporating Nociscan Into Their Scientific Practices for Power Low Again Ache Sufferers
MAGNETOM Flash is a Peer-to-Peer Journal Printed by Siemens to Showcase Advancing Applied sciences within the MRI Area
The RSNA Version Coincides With the Annual Assembly of the Radiology Society of North America (RSNA)
BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Firm”) ACON ACONW)), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to assist physicians establish the placement of power low again ache, introduced in the present day its Nociscan product is featured within the RSNA Version of Siemens Healthineers journal, MAGNETOM Flash. The RSNA annual assembly is December 1-4, 2024. The inclusion of Nociscan highlights the challenges of power low again ache and illustrates the rising significance of MR spectroscopy (MRS) as an progressive choice help instrument for physicians.
“Aclarion is happy to have Nociscan featured within the 2024 RSNA Version of MAGNETOM Flash,” stated Ryan Bond, Chief Technique Officer. “We’re honored to have famend physicians like Drs. Eastlack and Jabour illustrate how they make the most of Nociscan. We count on this text shall be an necessary function on the 2024 RSNA assembly and a beneficial reference for physicians and clinicians into 2025 and past, because the medical neighborhood continues adopting enhanced choice help instruments, like Nociscan, to resolve the low again ache diagnostic dilemma.”
MAGNETOM Flash is the peer-to-peer journal revealed by Siemens Healthineers and is obtainable to their clients world-wide. The journal was created almost 30 years in the past to showcase advancing applied sciences throughout the Siemens MR ecosystem, as illustrated by physicians and clinicians for the good thing about their friends. The journal presents scientific case research, software suggestions, technical and product info. The MAGNETOM Flash is obtainable to Siemens clients, certified physicians, technologists, physicists, and radiology departments.
Power low again ache (cLBP) is a worldwide healthcare drawback with roughly 266 million folks worldwide affected by degenerative backbone illness and low again ache. Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. When used with different diagnostic instruments, Nociscan gives important insights into the placement of a affected person’s low again ache.
For a replica of the Nociscan article, please e-mail: [email protected]
To discover a Nociscan middle, view our web site map here.
Extra details about MAGNETOM Flash, please go to: MAGNETOM Flash
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. Via a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives important insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch comprises forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, resembling “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to quite a lot of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Trade Fee. Readers are inspired to evaluation the part titled “Threat Elements” within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2023, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
[email protected]
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
[email protected]
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
